文献速递艾滋病与性传播感染

西班牙RELATIVITY研究:长效卡博特韦联合利匹韦林治疗HIV的前瞻性疗效与持久性评估

A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study).
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

RELATIVITY是一项为期5年的多中心、双向性、非对照队列研究,中期分析纳入3146例西班牙HIV感染者,评估长效注射卡博特韦联合利匹韦林的实际疗效与安全性。中位随访23个月,病毒学抑制维持率≥96%,6.4%因注射部位反应、全身不良事件或病毒学失败等原因停药。结果与随机试验一致,支持该方案在临床实践中的高有效性和安全性。

要点

  • 中位随访23个月,病毒学抑制维持率≥96%。
  • 总体停药率6.4%,最常见原因为注射部位反应。
  • 换药前中位ART时长9.0年,病毒抑制中位84.0个月。

核心结论

  • RELATIVITY中期结果证实长效卡博特韦联合利匹韦林在西班牙临床实践中具有高有效性和安全性,与随机试验及真实世界数据一致。

研究设计与样本

  • RELATIVITY为5年期、多中心、双向性、非对照队列研究,中期分析截止2025年3月1日,纳入西班牙58家医院的3203例患者,排除57例换药时病毒载量可检出者,最终分析3146例。

主要发现

  • 随访至23个月,病毒学抑制维持率≥96%。
  • 总体停药率6.4%(n=199),最常见原因为注射部位反应(n=45)、全身不良事件(n=29)和病毒学失败(n=20)。
  • 大多数为男性(84.6%),中位年龄45岁;换药前中位ART时长9.0(5.0-15.0)年,病毒抑制中位时长84.0(36.0-132.0)个月;77.1%既往使用过基于整合酶抑制剂的方案。

临床怎么用

  • 对于病毒学抑制的HIV感染者,长效卡博特韦联合利匹韦林可作为减少每日服药负担、治疗疲劳和污名化的替代方案。

局限性

  • 本研究为非对照队列研究,中期分析结果需更长期随访进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Daily oral antiretroviral therapy (ART) has transformed HIV into a chronic, manageable condition, but it still poses psychological, logistical, and biological challenges. Long-acting injectable (LAI) cabotegravir plus rilpivirine provides an alternative for virologically suppressed individuals, reducing treatment fatigue, stigma, and daily dosing. While clinical trials have demonstrated efficacy and safety, real-world data remain limited. We assessed the effectiveness and safety of LAI cabotegravir plus rilpivirine in Spain. METHODS: RELATIVITY is a 5-year, multicentre, ambispective, non-controlled cohort study. The primary endpoint was treatment effectiveness, defined as the proportion of patients discontinuing LAI therapy for any reason, including loss of virological suppression (HIV-RNA >50 copies/mL) during follow-up, regardless of formal failure criteria. RESULTS: This interim analysis (cut-off: March 1, 2025) included 3203 patients from 58 Spanish hospitals; 57 were excluded due to detectable viral load at switch, leaving 3146 participants. Most were men (84.6%), with a median age of 45 years. Median time on ART before switching was 9.0 (5.0-15.0) years, and duration of viral suppression was 84.0 (36.0-132.0) months. Prior integrase inhibitor-based regimens were reported in 77.1%. Virological suppression was maintained in ≥96% through 23 months of follow-up. Overall, 6.4% (n = 199) discontinued, most frequently for injection-site reactions (n = 45), systemic adverse events (n = 29), or virological failure (n = 20). CONCLUSIONS: Interim results from the RELATIVITY cohort confirm high effectiveness and safety of LAI cabotegravir plus rilpivirine in Spanish clinical practice, consistent with randomized trial outcomes and real-world data. An extended follow-up will provide further insights.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Buzón-Martín L, Montes ML, Pedrero R, et al. A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study). J Antimicrob Chemother. 2025. PMID: 41128149. doi:10.1093/jac/dkaf389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。